Recomendations for the prevention of adverse drug reactions in older adults with dementia;Recomendaciones en la prevención de reacciones adversas a medicamentos en personas mayores con demencia

Revista Espanola de Geriatria y Gerontologia

Volumn 45, Issue 2, 2010, Pages 89-96

  Gómez Pavón, Javier ^a   González García, Paloma ^b   Francés Román, Inés ^c   Vidán Astiz, Maite ^d   Gutiérrez Rodríguez, José ^e   Jiménez Díaz, Gregorio ^f   Montero Fernández, Nuria Pilar ^d   Álvarez Fernández, Baldomero ^g   Jiménez Páez, José María ^h  

^a HOSPITAL CENTRAL DE LA CRUZ ROJA   (Spain)

^b Unidad de Trabajo Social   (Spain)

^c Clínica Psicogeriátrica Josefina Arregui   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^e Ovida Asistencial   (Spain)

^f HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

^g HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^h Clínica Geriátrica   (Spain)

Author keywords

Adverse drugs reactions; Dementia; Elderly; Prevention

Indexed keywords

ADVERSE DRUG REACTION; COMORBIDITY; DEMENTIA; ELDERLY CARE; HUMAN; PATIENT COMPLIANCE; POLYPHARMACY; PRESCRIPTION; RISK FACTOR; SHORT SURVEY;

EID: 77949774970     PISSN: 0211139X     EISSN: 15781747     Source Type: Journal    
DOI: 10.1016/j.regg.2009.10.002     Document Type: Short Survey

References (100)

1. Gurwitz J.H., Field T.S., Harrold L.R., Rothschild J., Debellis K., Seger A.C., et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA 289 (2003) 1107-1116
2. Thomas E.J., and Brennan T.A. Incidence and types of drugs adverse events in elderly patients: Population based review of medical records. BMJ 320 (2000) 741-744
3. Chrischilles E.A., Segar E.T., and Wallace R.B. Self-reported adverse drug reactions and related resource use: A study of community-dwelling persons 65 years of age and older. Ann Inter Med 117 (1992) 634-640
4. Gurwitz J.H., Field T.S., Avorn J., McCormick D., Jain S., Eckler M., et al. Incidence and preventability of adverse drug events in nursing homes. Am J Med 109 (2000) 87-94
5. Mannesse C.K., Derkx F.H., De Ridder M.A., Man in 't Veld A.J., and Van der Cammen T.J. Contribution of adverse drug reactions to hospital admission of older patients. Age Ageing 29 (2000) 35-39
6. Beijer H.J.M., and De Blaey C.J. Hospitalizations caused by adverse drug reactions (ADR): A meta-analysis of observacional studies. Pharm World Sci 24 (2002) 46-54
7. Lazarou J., Pomeranz B., and Corey P. Incidence of adverse drug reaction in hospitalized patients. A metaanalisis of prospective studies. JAMA 279 (1998) 1200-1205
8. Gómez Pavón J., Martín Lesende I., Baztán Cortés J.J., Regato P., Formiga F., Segura Benedicto A., et al., (Grupo Impulsor). Grupos de trabajo de expertos de las sociedades científicas y administraciones sanitarias. Prevención de la dependencia en las personas mayores. Rev Esp Geriatr Gerontol 42 (2007) 15-56
9. Onder G., Pedone C., Landi F., Cesari M., Della Vedova C., Bernabei R., et al. Adverse drug reactions as cause of hospital admissions: Results from the Italian Group of Pharmacoepidemiology in the Elderly (GIFA). J Am Geriatr Soc 50 (2002) 1962-1968
10. Laroche M.L., Charmes J.P., Nouaille Y., Picard N., and Merle L. Is inappropriate medication use a major cause of adverse drug reactions in the elderly?. Br J Clin Pharmacol 63 (2007) 177-186
11. Davies E.C., Green C.F., Taylor S., Williamson P.R., Mottram D.R., and Pirmohamed M. Adverse drug reactions in hospital in-patients: A prospective analysis of 3695 patient-episodes. PLoS One 4 (2009) e4439
12. Vilà A., San José A., Roure C., Armadans L., and Vilardell M. Estudio multicéntrico prospectivo de reacciones adversas a medicamentos en pacientes ancianos hospitalizados. Med Clin (Barc) 120 (2003) 613-618
13. Franceschi M., Scarcelli C., Niro V., Seripa D., Pazienza A.M., Pepe G., et al. Prevalence, clinical features and avoidability of adverse drug reactions as cause of admission to a geriatric unit: A prospective study of 1756 patients. Drug Saf 31 (2008) 545-556
14. Zhang M., Holman C.D., Price S.D., Sanfilippo F.M., Preen D.B., and Bulsara M.K. Comorbidity and repeat admission to hospital for adverse drug reactions in older adults: Retrospective cohort study. BMJ 337 (2008) 2752-2756
15. Passarelli M.C., Jacob-Filh W., and Figuera A. Adverse drug reactions in an elderly hospitalised population inappropriate prescription is a leading cause. Drugs Aging 22 (2005) 767-777
16. Juntti-Patinen L., and Neuvonen P.J. Drug related deaths in a university central hospital. Eur J Clin Pharmacol 58 (2002) 479-482
17. Howard R.L., Avery A.J., Slavenburg S., Royal S., Pipe G., Lucassen P., et al. Which drugs cause preventable admissions to hospital? A systematic review. Br J Clin Pharmacol 63 (2007) 136-147
18. Arlt S., Lindner R., Rösler A., and Von Rentelnkruser W. Adherence to medication in patient with dementia. Predictor and strategies for improvement. Drugs Aging 25 (2008) 1033-1047
19. Cummings J. Alzheimer's disease. N Eng J Med 351 (2004) 56-67
20. Garton M.J., Keir G., Lakshmi M.V., and Thompson E.J. Age-related changes in cerebrospinal fluid protein concentrations. J Neurol Sci 104 (1991) 74-80
21. Jackson K., Gordon S., Hart R., Hopkin R., and Ely N. The association between delirium and cognitive decline: A review of the empirical literature. Neuropsychol Rev 12 (2004) 87-98
22. Marín Carmona J.M. Delirium y demencia. Rev Esp Geriatr Gerontol 43 (2008) 42-46
23. Formiga F., Fort I., Robles M.J., Riu S., Rodríguez D., and Sabartes O. Aspectos diferenciales de comorbilidad en pacientes ancianos con demencia tipo Alzheimer o con demencia vascular. Rev Neurol 46 (2008) 72-76
24. Schubert C., Bustani M., and Callahan C. Comorbility profile of dementia patients in Primary Care: Are they siscker?. J Am Geriatr Soc 54 (2006) 104-111
25. Han L., Agostini J.V., and Allore H.G. Cumulative anticholinergic exposure is associated with poor memory and executive function in older men. J Am Geriatr Soc 56 (2008) 2203-2210
26. Fick D., Kolanowski A., and Waller J. High prevalence of central nervous system medications in community-dwelling older adults with dementia over a three-year period. Aging Ment Health 11 (2007) 588-595
27. Sloane P.D., Zimmerman S., Brown L.C., Ives T.J., and Walsh J.F. Inappropriate medication prescribing in residential care/assisted living facilities. J Am Geriatr Soc 50 (2002) 1001-1011
28. Prudent M., Dramé M., Jolly D., Trenque T., Parjoie R., Mahmoudi R., et al. Potentially inappropriate use of psychotropic medications in hospitalized elderly patients in France: Cross-sectional analysis of the prospective, multicentre SAFEs cohort. Drugs Aging 25 (2008) 933-946
29. Lyketsos C.G., Toone L., Tschanz J., Rabins P.V., Steinberg M., Onyike C.H., et al. Population-based study of medical comorbidity in early dementia and 'cognitive impairment, no dementia (CIND)': Association with functional and cognitive impairment: The Cache County Study. Am J Geriatr Psychiatry 13 (2005) 656-664
30. Zekry D., Herrmann F.R., Grandjean R., Meynet M.P., Michel J.P., Gold G., et al. Demented versus non-demented very old inpatients: The same comorbidities but poorer functional and nutritional status. Age Ageing 37 (2008) 83-89
31. San José Laporte A. Optimización en el uso de los medicamentos en las personas mayores hospitalizadas. In: López A., Formiga F., Ruiz D., and Duaso E. (Eds). Clínicas en geriatría hospitalaria (2006), Scientific Communication Management, Madrid 43-52
32. Ernst F.D., and Grizzle A.J. Drug-related morbidity and mortality: Updating the cost of illness model. J Am Pharm Assoc 41 (2001) 192-199
33. Bootman J.L., Harrison D.L., and Cox E. The health care cost of drug-related morbidity and mortality in nursing facilities. Arch Intern Med 157 (1997) 2089-2096
34. Gallagher P., Ryan C., Byrne S., Kennedy J., and O'Mahony D. STOPP (Screening Tool of Older Person's Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment). Consensus validation. Int J Clin Pharmacol Ther 46 (2008) 72-83
35. Delgado E., Muñoz M., Montero B., Sánchez C., Gallaguer P.F., and Cruz-Jentoft A.J. Prescripción inapropiada de medicamentos en los pacientes mayores: los criterios STOPP/START. Rev Esp Geriatr Gerontol 44 (2009) 273-279
36. Shrank W.H., Polinski J.M., and Avorn J. Quality indicators for medication use in vulnerable elders. J Am Geriatr Soc 55 (2007) S373-S382
37. Merle L., Laroche M.L., Dantoine T., and Charmes J.P. Predicting and prevention adverse drug reactions in the very old. Drugs Aging 22 (2005) 375-392
38. Gracia S., Montañes R., Bover J., Cases A., Deulofeu P., De Francisco A.L.M., et al. Documento de consenso: recomendaciones sobre la utilización de ecuaciones para la estimación del filtrado glomerular en adultos. Nefrología 26 (2006) 658-665
39. Roter D.L. Effectiveness of interventions to improve patient compliance: A meta-analysis. Med Care 36 (1998) 1138-1161
40. Guehne U., Riedel-Heller S., and Angermeyer M.C. Mortality in dementia. Neuroepidemiology 25 (2005) 153-162
41. Kukull W.A., Brenner D.E., Speck C.E., Nochlin D., Bowen J., McCormick W., et al. Causes of death associated with Alzheimer disease: Variation by level of cognitive impairment before death. J Am Geriatr Soc 42 (1994) 723-726
42. Gambassi G., Landi F., and Lapane K.L. Predictors of mortality in patients with Alzheimer's disease living in nursing homes. J Neurol Neurosurg Psychiatry 67 (1999) 59-65
43. Mielke M.M., Rosenberg P.B., Tschanz J., Cook L., Corcoran C., Hayden K.M., et al. Vascular factors predict rate of progression in Alzheimer disease. Neurology 69 (2007) 1850-1858
44. Finucane T.E., Christmas C., and Travi K. Tube feeding in patients with advanced dementia: A review of the evidence. JAMA 282 (1999) 1365-1370
45. Horikawa E., Matsui T., Arai H., Seki T., Iwasaki D., and Sasaki H. Risk of falls in Alzheimer's disease: A prospective study. Inter Med 44 (2005) 412-417
46. Sto Y., Kanoko T., Satoh K., and Iwamoto J. The prevention of hip fracture with risedronate and ergocalciferol plus calcium supplementation in elderly women with Alzheimer disease: A randomized controlled trial. Arch Intern Med 165 (2005) 1737-1742
47. Guía de buena práctica clínica en Geriatría. Anciano afecto de fractura de cadera. Avellana Zaragoza J.A., Ferrández Portal L, coords. Madrid: Elsevier Doyma; 2007.
48. Leong I.Y., and Nuo T.H. Prevalence of pain in nursing home residents with different cognitive and communicative abilities. Clin J Pain 23 (2007) 119-127
49. Woolf S.H., Battista R.N., Anerson G.M., Logan A.G., and Wang E.E.L. Assessing the clinical effectiveness of preventive manoeuvres: Analytical principles and systematic methods in reviewing evidence and developing clinical practice recommendations. J Clin Epidemiol 43 (1994) 891-905
50. Hogan D.B., Bailey P., Black S., Carswell A., Cherktow H., Clarke B., et al. Diagnosis and treatment of dementia: 4. Approach to management of mild to moderate dementia. CMAJ 179 (2008) 787-793
51. Hogan D.B., Bailey P., Black S., Carswell A., Cherktow H., Clarke B., et al. Diagnosis and treatment of dementia: 5. Nonpharmacologic and pharmacologic therapy for mild to moderate dementia. CAMJ 179 (2008) 1019-1026
52. Herrmann N., and Gauthier S. Diagnosis and treatment of dementia: 6. Management of severe Alzheimer disease. CAMJ 179 (2008) 1279-1287
53. Waldemar G., Dubois B., Emre M., Georges J., McKeith I.G., Rossor M., et al. Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline. Eur J Neurol 14 (2007) e1-e26
54. American Psychiatric Association. Practice guidelines for the treatment of patients with Alzheimer's disease and other dementias. Second edition. Am J Psychiatry 164 (2007) 1-56
55. Burns A., O'Brien J., and BAP Dementia Consensus group. Clinical practice with anti-dementia drugs: A consensus statement from British Association for Psychopharmacology. J Psychopharmacol 20 (2006) 732-735
56. Lanctôt K.L., Herrmann N., Yau K.K., Khan L.R., Liu B.A., LouLou M.M., et al. Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: A meta-analysis. CMAJ 169 (2003) 557-564
57. o: CD003159. doi:10.1002/14651858.CD003159.
58. o: CD000147. doi:10.1002/14651858.CD000147
59. o: CD001011. doi:10.1002/14651858.CD001011.
60. o: CD003120. doi:10.1002/14651858.CD003120.pub3.
61. o: CD000442. doi:10.1002/14651858.CD000442.
62. o: CD002854. doi:10.1002/14651858.CD002854.pub2.
63. o: CD003799. doi:10.1002/14651858.CD003799.pub2.
64. o: CD003160. doi:10.1002/14651858.CD003160.pub2.
65. Pantoni L., Bianchi C., Beneke M., Inzitari D., Wallin A., and Erkinjuntti T. The Scandinavian multi-infarct dementia trial: A double-blind, placebo-controlled trial on nimodipine in multi-infarct dementia. J Neurol Sci 175 (2000) 116-123
66. Sha M.C., and Callahan C.M. The efficacy of pentoxifylline in the treatment of vascular dementia: A systematic review. Alzheimer Dis Assoc Disord 17 (2003) 46-54
67. o: CD001296. doi:10.1002/14651858.CD001296.
68. Frisoni G.B., Rozzini L., Gozzetti A., Binetti G., Zanetti O., Bianchetti A., et al. Behavioral síndromes in Alzheimer' disease: Description and correlates. Dement Geriatr Cogn Disord 10 (1999) 130-138
69. Schneider L.S., Dagerman K., and Insel P.S. Efficacy and adverse effects of atypical antipsychotics for dementia: Metaanalysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry 14 (2006) 191-210
70. o: CD003476. doi:10.1002/14651858.CD003476.pub2.
71. Schneider L.S., Tariot P.N., Dagerman K.S., Davis S.M., Hsiao J.K., Ismail M.S., et al., CATIE-AD Study Group. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer' disease. N Eng J Med 355 (2006) 1525-1538
72. Sultzer D.L., Davis S.M., Tariot P.N., Dagerman K.S., Lebowitz B.D., Lyketsos C.G., et al. Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: Phase 1 outcomes from the CATIE-AD effectiveness trial. Am J Psychiatry 165 (2008) 844-854
73. Schneider L.S., Dagerman K.S., and Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: Meta-analysis of randomized placebo-controlled trials. JAMA 294 (2005) 1934-1943
74. Kales H.C., Valenstein M., Kim H.M., McCarthy J.F., Ganoczy D., Cunningham F., et al. Mortality risk in patients with dementia treated with antipsychotics versus other psychiatric medications. Am J Psychiatry 164 (2007) 1568-1576
75. Wang P.S., Schneeweiss S., Avorn J., Fischer M.A., Mogun H., Solomon D.H., et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 353 (2005) 2335-2341
76. Schneeweiss S., Setoguchi S., Brookhart A., Dormuth C., and Wang P.S. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. CMAJ 176 (2007) 627-632
77. Gill S.S., Bronskill S.E., Normand S.L., Anderson G.M., Sykora K., Lam K., et al. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med 146 (2007) 775-786
78. Salzman C., Jeste D.V., Meyer R.E., Cohen-Mansfield J., Cummings J., Grossberg G.T., et al. Elderly patients with dementia-related symptoms of severe agitation and aggression: Consensus statement on treatment options, clinical trials methodology, and policy. J Clin Psychiatry 69 (2008) 1889-1898
79. Jeste D.V., Blazer D., Casey D., Meeks T., Salzman C., Schneider L., et al. ACNP white paper: Update on use of antipsychotic drugs in elderly persons with dementia. Neuropsychopharmacology 33 (2008) 957-970
80. Grimmer T., and Kurz A. Effects of cholinesterase inhibitors on behavioural disturbances in Alzheimer's disease: A systematic review. Drugs Aging 23 (2006) 957-967
81. Wilcock G.K., Ballard C.G., Cooper J.A., and Loft H. Memantine for agitation/agression and psychosis in moderately severe to severe Alzheimer's disease: A pooled analysis of 3 studies. J Clin Psychiatry 69 (2008) 341-348
82. Rodda J., Morgan S., and Walker Z. Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine. Int Psychogeriatr 19 (2009) 1-12
83. Sink D.M., Holden D.F., and Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia. JAMA 293 (2005) 596-608
84. Alexopoulos G.S., Streim J., Carpenter D., and Docherty J.P. Expert consensus panel for using antipsychotic drugs in older patients. J Clin Psychiatry 65 (2004) 1-105
85. Benoit M., Arbus C., Blanchard F., Camus V., Cerase V., Clement J.P., et al. Professional consensus on the treatment of agitation, aggressive behavior, oppositional behaviour and psychotic disturbances in dementia. J Nutr Health Aging 5 (2006) 410-415
86. American Geriatrics Society and American Association for Geriatric Psychiatry. Consensus statement on improving the quality of mental health care in US nursing homes: Management of depression and behavioral symptoms associated with dementia. J Am Geriatr Soc 51 (2003) 1287-1298
87. McKeith I., Del Ser T., Spano P., Emre M., Wesnes K., Anand R., et al. Efficacy of rivastigmine in dementia with Lewy bodies: A randomized, double-blind, placebo-controlled international study. Lancet 356 (2000) 2031-2036
88. Thompson S., Herrmann N., Rapoport M.J., and Lanctôt K.L. Efficacy and safety of antidepressants for treatment of depression in Alzheimer's disease: A metaanalysis. Can J Psychiatry 52 (2007) 248-255
89. Konovalov S., Muralee S., and Tampi R.R. Anticonvulsants for the treatment of behavioral and psychological symptoms of dementia: A literature review. Int Psychogeriatr 20 (2008) 293-308
90. Tariot P.N., Erb R., Leibovici A., Podgorski C.A., Cox C., Asnis J., et al. Carbamazepine treatment of agitation in nursing home patients with dementia: A preliminary study. J Am Geriatr Soc 42 (1994) 1160-1166
91. Olin J.T., Fox L.S., Pawluczyk S., Taggar N.A., and Schneider L.S. A pilot randomized trial of carbamazepine for behavioral symptoms in treatment-resistant outpatients with Azheimer disease. Am J Geriatr Psychiatry 9 (2001) 400-405
92. Pinheiro D. Anticonvulsant mood stabilizers in the treatment of behavioral and psychological symptoms of dementia. Encephale 34 (2008) 409-415
93. Porsteinsson A.P., Tariot P.N., Erb R., Cox C., Smith E., Jakimovich L., et al. Placebo-controlled study of divalproex sodium for agitation in dementia. Am J Geriatr Psychiatry 9 (2001) 58-66
94. Porsteinsson A.P., Tariot P.N., Jakimovich L.J., Kowalski N., Holt C., Erb R., et al. Valproate therapy for agitation in dementia: Open-label extension of a double-blind trial. Am J Geriatr Psychiatry 11 (2003) 434-440
95. Tariot P.N., Raman R., Jakimovich L., Schneider L., Porsteinsson A., Thomas R., et al. Divalproex sodium in nursing home residents with posible or probable Alzheimer disease complicated by agitation: A randomized, controlled trial. Am J Geriatr Psychiatry 13 (2005) 942-949
96. Herrmann N., Lanctôt K.L., Rothenburg L.S., and Eryavec G. A placebo-controlled trial of valproate for agitation and aggression in Alzheimer'disease. Dement Geriatr Cogn Disord 23 (2007) 116-119
97. Herrmann N., Lanctot K., and Myszack M. Effectiveness of gabapentin for the treatment of behavioral disorders in dementia. J Clin Psychopharmacol 20 (2000) 90-93
98. Aulakh J.S., Hawkins J.W., Athwal H.S., Sheikh J.I., Yesavage J., and Tinklenberg J.R. Tolerability and effectiveness of lamotrigine in complex elderly patients. J Geriatr Psychiatry Neurol 18 (2005) 8-11
99. Fhager B., Meiri I.M., Sjögren M., and Edman A. Treatment of aggressive behavior in dementia with the anticonvulsant topiramate: A retrospective pilot study. Int Psychogeriatr 15 (2003) 307-309
100. Pollock B.G., Mulsant B.H., Rosen J., Mazumdar S., Blakesley R.E., Houck P.R., et al. A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia. Am J Geriatr Psychiatry 15 (2007) 942-952